Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Hologic Promotions; New Hires at Insight Genetics


Hologic President and CEO John Cumming disclosed during the company's third-quarter earnings call this week that the company has promoted Rohan Hastie to the position of group vice president, and David Harding to the position of group vice president, women's health.

Hastie has served in a number of senior-level roles at Hologic, most recently as general manager of diagnostics. Previously, he had senior roles in Hologic's molecular business and corporate development group. He joined Hologic from strategic advisory firm PA Consulting, Cumming said.

Harding previously served as leader of Hologic's international team, and has also managed the company's Interventional Breast Solutions business. Prior to this, Harding served as a principal at McKinsey.

Nashville, Tenn.-based molecular diagnostics firm Insight Genetics this week announced the hiring of three employees and the promotion of another, according to a report in The Nashville Post.

David Burg has joined the company as associate director of business development. Burg will lead sales and marketing for the company's Insight Molecular Labs. Prior to joining Insight, Burg was regional sales director for Response Genetics. He has also been a senior executive oncology account manager with GlaxoSmithKline.

Insight has also hired Dan Bailey as senior associate of new product planning, and Tyler Nielsen as a research associate; and has promoted Lindsay Chatfield to the role of research associate.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.